At the news
? NEUTRALIMPACT 3/10 PRESS-RELEASE filed Nov 3, 2026 at 07:15 ET
Decoy Therapeutics reported Q3 2026 cash of $8.1M and provided a pipeline update. The lead pan-coronavirus program is expected to file a CTA/IND in 2H 2027, with once-weekly dosing potential shown in preclinical studies. No revenue or EPS was reported; the company remains pre-revenue with a cash runway that may fund operations into 2027.
- Cash on balance sheet was $8.1 million at September 30, 2026, including ~$2.5M restricted Gates Foundation grant funding.
- Lead pan-coronavirus program expected to file CTA/IND in 2H 2027.
- Optimized lead candidate showed potential for once-weekly dosing in preclinical studies.
- Pan-filovirus program targeting Ebola, Marburg and related viruses is being explored.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access